Sapient

#Biomarkerdiscovery partner to pharma & biotechs, transforming drug development by enabling discovery of dynamic #biomarkers at unprecedented speed & scale.

[Sapient @SapientBio]

Blood‑based biomarkers are reshaping #Alzheimers research. With this multiplexed assay, you get absolute quantification of five key CNS markers in one workflow:
Offered by Sapient, an Alamar Biosciences Certified Service Provider.
Request the assay: https://t.co/atsZdEm3AS

[Sapient @SapientBio]

Proving Target Relevancy with FFPE Proteomics

This session shows how FFPE proteomics enables direct measurement of functional biology- revealing protein expression, pathway activation, immune activity, and resistance mechanisms in archived samples.

https://t.co/thmrQDG7B4

[Sapient @SapientBio]

Sapient’s Mo Jain, MD PhD shares with The Analytical Scientist how multi‑omics platforms are using AI to translate massive molecular data into real clinical insight - accelerating biomarker discovery, trial design, and diagnostic innovation.
🔗 https://t.co/xJHl85tzYa

[Sapient @SapientBio]

New case study: Inflammatory profiling with NULISAseq™ + Sapient’s discovery #proteomics & #metabolomics uncovers previously unrecognized immune modulation in response to #GLP1 therapy.
Preview & download the full dataset: https://t.co/ftfsGyKB1A

[Sapient @SapientBio]

Metabolomics goes beyond genomics-capturing environmental, microbial & drug‑related biology in one readout. By measuring endogenous + exogenous #metabolites, it reveals how exposures shape disease.
See more use cases: https://t.co/987M8Qp9HT

[Sapient @SapientBio]

De‑risk high‑value #Alzheimers programs with one blood‑based panel.
The NULISAqPCR™ AD 5‑plex Assay quantifies BD‑pTau217, Aβ42, GFAP, NfL & APOE4 – delivering a multidimensional readout of pathology, inflammation & #neurodegeneration.
Learn more: https://t.co/atsZdEm3AS

[Sapient @SapientBio]

Traditional biomarker panels miss the complexity of human biology. Sapient changes that with actionable omics – scalable, high‑resolution protein, metabolite, lipid & cytokine profiling that reveals real biology, not inferences.
Meet with our scientists: https://t.co/i9qLNuLs10

[Sapient @SapientBio]

Now available: NULISAqPCR™ AD 5‑plex Assay.
Absolute quant of 5 key Alzheimer’s biomarkers-BD‑pTau217, NfL, Aβ42, GFAP, APOE4- from one ultra‑sensitive blood assay. Fast, high‑performance, and ideal for early detection + translational studies.
https://t.co/atsZdEm3AS
#ADassay

[Sapient @SapientBio]

Metabolomics is complex – but foundation models can finally make it actionable. See how they unlock clinical trial insights on heterogeneity, risk, and design.
https://t.co/fA7pZRASXY
#metabolomics #foundationmodel #foundationmodeling

[Sapient @SapientBio]

Why do patients with the same diagnosis respond differently to the same drug?
Because human biology is heterogeneous—and that complexity can’t be captured by genomics or single biomarkers alone.
Learn more here 👉 https://t.co/tTVoDh7jN9
#AI #Metabolomics

[Sapient @SapientBio]

Upcoming Webinar | Proving Target Relevancy with FFPE Proteomics
Learn how next‑gen FFPE proteomics delivers direct, functional human evidence to validate targets and reduce late‑stage failures in precision oncology.
🔗 Register to attend the live event: https://t.co/sF8KKtNZgD

[Sapient @SapientBio]

“AI reveals structure in biological complexity that humans can’t define manually—and orthogonal validation is what makes those signals trustworthy.”
— Mo Jain, MD PhD, in The Analytical Scientist
#AI #Omics #Biomarkers 🔗https://t.co/9rpbDo00iu

[Sapient @SapientBio]

Did you know? Plasma metabolomics reveals system‑wide biology invisible to tissue‑specific markers.
By capturing circulating metabolites from multiple organs, it enables a holistic view of physiology, disease, and biomarker discovery.
🔗 https://t.co/Ppmzn2hQcQ
#Metabolomics

[Sapient @SapientBio]

Unlock biomarker insights & responder profiles from #FFPE samples.
Sapient’s FFPE Multi-Omics Platform analyzes archived tissue to:
• Optimize stratification & dosing
• Identify target engagement
• Select responder subgroups
#ClinicalOncology study: https://t.co/lz0GC3hFNe

[Sapient @SapientBio]

#Metabolomics reveals phenotypic differences missed by genes or labs. Sapient uncovers:
• Therapy-response differences
• Exposure-modified genetic risk
• Biology behind phenotypic variation
• Metabolic signals before disease
#WhiteSheet: https://t.co/Ppmzn2hQcQ

[Sapient @SapientBio]

Looking for a protein or target to modulate?

Explore Sapient’s interactive Protein Assay Menu –12,000+ proteins by mass spectrometry:
https://t.co/bRhcBv7ffA
Analyze proteins & PTMs across plasma, cells, and tissue (incl. FFPE).
Search by protein, gene, pathway, or phenotype.

[Sapient @SapientBio]

Using large-scale #Metabolomics (1,600 samples), our #ML aging clock shows:
• Accelerated aging in chronic disease
• Severity-linked acceleration
• Reversal after therapy (e.g., transplant)
Case study: https://t.co/Ab8VFaO5vX

[Sapient @SapientBio]

AI in analytical science isn’t about hype-it’s about scale and context.

#Multiomics + AI moves us beyond single biomarkers toward true systems-level disease models.

Dr. Mo Jain discussed this with The Analytical Scientist: https://t.co/xJHl85tzYa

[Sapient @SapientBio]

White Paper: MS-based #FFPE proteomics marks a turning point in oncology R&D.

Direct quantification of tumor protein function -isoforms, PTMs, pathway activation, and resistance -without antibodies.

Learn more: https://t.co/m2qvtfLbJq

[Sapient @SapientBio]

Get more from your #FFPE samples.
Turn archival tissue into a discovery engine.

Sapient’s FFPE Proteomics measures 10,000+ proteins across key oncogenes, drug targets & pathways to unlock new #biomarker insights.

➡️ https://t.co/ICWNiC7vXI